Revisiting the FDA’s Accelerated Approval Pathway

This article discusses key components of the FDA’s recent guidance and suggests how the FDA could clarify expectations for confirmatory trials and management of uncertainty regarding product safety.

Corresponding Author: Asha Kodan, MD, Department of Medicine, Johns Hopkins University School of Medicine, 733 N Broadway, Baltimore, MD 21205 (akodan1@jh.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.